Kaleido Biosciences, Inc. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported net loss was USD 90.29 million compared to USD 81.62 million a year ago. Basic loss per share from continuing operations was USD 2.16 compared to USD 2.44 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | 0.00% | 0.00% | +9,900.00% |
2022 | Kaleido Biosciences, Inc.(NasdaqGS:KLDO) dropped from S&P Global BMI Index | CI |
2022 | Kaleido Biosciences, Inc.(NasdaqGS:KLDO) dropped from S&P TMI Index | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+9,900.00% | 4.26K | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- KLDO Stock
- News Kaleido Biosciences, Inc.
- Kaleido Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021